Venus Remedies Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Circuit Breaker Trigger

On 9 Feb 2026, Venus Remedies Ltd’s share price plunged to an intraday low of ₹697.75, marking a 5.0% decline from its previous close. This sharp fall triggered the maximum permissible daily price band of ₹5, resulting in the stock hitting its lower circuit. The stock’s high for the day was ₹739.00, indicating significant volatility and a wide intraday range of ₹41.25.

The weighted average price for the day was closer to the low end of the band, signalling that the bulk of trading volume occurred near the bottom price levels. Total traded volume stood at 0.24972 lakh shares, translating to a turnover of approximately ₹1.78 crore. Despite this turnover, the stock’s liquidity remains moderate, with the ability to support trade sizes up to ₹0.04 crore based on 2% of the five-day average traded value.

Persistent Downtrend and Sector Comparison

Venus Remedies Ltd has been on a consistent downward trajectory, losing 11.56% over the past seven trading sessions. This underperformance is stark when compared to the Pharmaceuticals & Biotechnology sector, which gained 1.31% on the same day, and the Sensex, which rose by 0.64%. The stock’s one-day return of -1.72% further emphasises the divergence from broader market and sector trends.

The sustained decline suggests growing investor apprehension, possibly driven by concerns over company-specific fundamentals or broader market sentiment affecting micro-cap pharmaceutical stocks. The stock’s moving averages present a mixed technical picture: while the price remains above the 100-day and 200-day moving averages, it is trading below the 5-day, 20-day, and 50-day averages, indicating short- to medium-term bearish momentum.

Investor Participation and Delivery Volumes

Investor participation appears to be waning amid the ongoing downtrend. Delivery volumes, a key indicator of genuine investor interest, have declined sharply. On 6 Feb 2026, delivery volume was recorded at 2,040 shares, down by 46.58% compared to the five-day average delivery volume. This drop suggests that fewer investors are holding the stock for the long term, with many possibly exiting positions amid the negative price action.

The falling delivery volumes combined with the lower circuit hit indicate panic selling and a lack of fresh buying interest to absorb the supply. The unfilled supply at lower price levels has contributed to the circuit limit being reached, preventing further price declines during the trading session.

Fundamental and Market Context

Venus Remedies Ltd operates within the Pharmaceuticals & Biotechnology industry, a sector that has generally shown resilience and growth potential. The company’s market capitalisation stands at ₹976 crore, categorising it as a micro-cap stock. Despite the recent downgrade from a Strong Buy to a Buy rating on 1 Feb 2026, the stock maintains a respectable Mojo Score of 70.0, reflecting favourable fundamentals and growth prospects relative to peers.

The downgrade in rating may have contributed to the negative sentiment, as investors recalibrate expectations. The company’s Market Cap Grade is 4, indicating moderate size and liquidity constraints typical of micro-cap stocks. Such stocks often experience amplified price swings and volatility, especially during periods of market uncertainty or sector rotation.

Technical Analysis and Moving Averages

From a technical standpoint, Venus Remedies Ltd’s share price is currently trading above its long-term moving averages (100-day and 200-day), which can be interpreted as a sign of underlying strength over a longer horizon. However, the price is below the short-term moving averages (5-day, 20-day, and 50-day), signalling bearish momentum in the near term.

This divergence suggests that while the stock may have solid fundamentals, short-term traders and investors are cautious, possibly awaiting clearer signs of a reversal or positive catalysts before re-entering. The seven consecutive days of decline and the recent lower circuit hit underscore the prevailing negative sentiment.

Implications for Investors

The recent price action in Venus Remedies Ltd highlights the risks associated with micro-cap pharmaceutical stocks, which can be prone to sharp volatility and sudden price movements. The seven-day losing streak and the lower circuit hit reflect a phase of panic selling and unfilled supply, which may deter short-term investors.

However, the company’s Mojo Grade of Buy and a solid Mojo Score of 70.0 suggest that the stock retains underlying quality and potential for recovery. Investors with a longer-term horizon may view the current weakness as an opportunity to accumulate shares at more attractive valuations, provided they are comfortable with the inherent risks.

It is advisable for investors to monitor upcoming corporate developments, sector trends, and broader market conditions closely. Additionally, tracking delivery volumes and price action around key moving averages can provide valuable insights into the stock’s likely direction in the near term.

Conclusion

Venus Remedies Ltd’s hit to the lower circuit on 9 Feb 2026 amid heavy selling pressure underscores the challenges faced by micro-cap stocks in volatile market environments. Despite the recent downgrade in rating and short-term bearish momentum, the company’s fundamental strength and sector positioning offer a balanced outlook for investors willing to navigate the risks.

Careful analysis of technical indicators, investor participation, and market sentiment will be crucial in assessing the stock’s potential recovery or further downside. As always, diversification and risk management remain key when dealing with stocks exhibiting such pronounced price swings.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →